Bunkerhill ECG-EF vs Imbio PHA (4.0.0)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Bunkerhill ECG-EF

by Bunkerhill Health

Imbio PHA (4.0.0)

by Imbio (a subsidiary of 4DMedical)

AI Verdict

Bunkerhill ECG-EF and Imbio PHA (4.0.0) are adjacent healthcare AI tools, both contributing to cardiac risk assessment but utilizing distinct diagnostic modalities. Bunkerhill ECG-EF analyzes ECGs to identify reduced left ventricular ejection fraction for heart failure risk, while Imbio PHA processes CT pulmonary angiograms to measure cardiac structures for assessing right ventricular dilation, pulmonary embolism, and hypertension. Therefore, selection depends on the specific imaging modality available and the primary cardiac condition being evaluated.

Choose Bunkerhill ECG-EF if…

Choose Bunkerhill ECG-EF if you need a rapid, non-invasive, and accessible tool for early identification of patients at risk for heart failure using routine 12-lead electrocardiograms. This software is ideal for broad screening in settings like primary care or emergency medicine to detect reduced left ventricular ejection fraction from readily available ECG data.

View Bunkerhill ECG-EF →

Choose Imbio PHA (4.0.0) if…

Choose Imbio PHA (4.0.0) if you require automated, precise measurements of cardiac structures from CT pulmonary angiogram (CTPA) scans to assess right ventricular dilation. This tool is best suited for aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension, providing critical insights from imaging data for specialized cardiology, pulmonology, or radiology workflows.

View Imbio PHA (4.0.0) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Bunkerhill ECG-EF	Imbio PHA (4.0.0)
Pricing	Contact sales for pricing details.	Unknown
Deployment	Cloud-native platform (Carebricks) that integrates with existing health system infrastructure like EHRs.	Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel).
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Bunkerhill ECG-EF

Tool A, Bunkerhill ECG-EF, leverages routine 12-lead ECG data, which is widely available and non-invasive, making it highly accessible and easily integrated into existing primary care and general cardiology workflows. Its 'software-only' nature further suggests simpler deployment and maintenance compared to solutions requiring specialized imaging equipment.

Clinical Value

Tie

Both tools offer significant clinical value by addressing critical diagnostic and risk stratification needs for serious cardiac and pulmonary conditions. Tool A aids in the early identification of heart failure risk from a common, non-invasive test, while Tool B provides automated, precise measurements from specialized imaging to assist in the diagnosis and risk stratification of pulmonary embolism and hypertension. Both are FDA-cleared, indicating validated clinical utility.

Pricing & Value

Tie

Both Bunkerhill ECG-EF and Imbio PHA require direct contact for pricing information, indicating a lack of public pricing transparency. Without specific pricing details or comprehensive return-on-investment studies for either product, it is not possible to definitively determine which offers superior financial value.

Enterprise Readiness

Imbio PHA (4.0.0)

While both tools are FDA-cleared, HIPAA compliant, and offer Business Associate Agreements, Tool B (Imbio PHA) explicitly states its HIPAA compliance is 'third-party certified by compliancy group,' providing an added layer of assurance. Furthermore, Imbio offers more flexible deployment options, including Cloud, Enterprise (on-premise), or via partners, catering to diverse enterprise IT environments.

Innovation

Bunkerhill ECG-EF

Bunkerhill ECG-EF is part of the broader Carebricks platform, which emphasizes 'Generative AI for clinical reasoning and action.' Recent developments like 'Carebricks Chat' demonstrate its capability to analyze unstructured patient data and provide conversational access to medical history, suggesting a more advanced and comprehensive application of AI beyond automated detection.

Support & Docs

Imbio PHA (4.0.0)

Imbio PHA provides clear and accessible support channels, including phone support, email, and an online case submission form, with stated 24/7/365 availability. They also offer readily available user manuals and product documentation for various versions. In contrast, Bunkerhill Health's public information does not explicitly detail specific customer support channels or publicly available documentation for its ECG-EF product.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Bunkerhill ECG-EF	Imbio PHA (4.0.0)
Name	Bunkerhill ECG-EF	Imbio PHA (4.0.0)
Company	BunkerHill Health	Imbio
Primary Data Input	Routine 12-lead electrocardiograms (ECGs)	CT pulmonary angiogram (CTPA) scans
Key Detection/Measurement	Reduced Left Ventricular Ejection Fraction (LVEF u2264 40%)	Automated measurement of right and left ventricle diameters, main pulmonary artery and aorta diameters; RV/LV and PA/Ao ratios
Specialties	Cardiology, Emergency Medicine, Internal Medicine	Cardiology, Pulmonology, Radiology
Output Format	Not specified	Annotated DICOM images, summary reports in PDF format

Videos

Demos, reviews, and walkthroughs featuring Bunkerhill ECG-EF and Imbio PHA (4.0.0).

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What type of patient data is required for each tool?

Bunkerhill ECG-EF analyzes routine 12-lead electrocardiograms (ECGs) to detect reduced left ventricular ejection fraction. Imbio PHA (4.0.0) processes CT pulmonary angiogram (CTPA) scans to measure cardiac structures.

What specific cardiac conditions or measurements does each AI tool help identify?

Bunkerhill ECG-EF detects reduced left ventricular ejection fraction (LVEF u2264 40%) to aid in the early identification of patients at risk for heart failure. Imbio PHA (4.0.0) automatically measures right and left ventricle diameters, main pulmonary artery and aorta diameters, and calculates RV/LV and PA/Ao ratios to assess potential right ventricular dilation, aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension.

How do these tools integrate into existing clinical workflows?

Bunkerhill ECG-EF integrates seamlessly with Electronic Health Records (EHRs) and clinical archives. Imbio PHA (4.0.0) can be deployed via Cloud, Enterprise (on-premise), or partners, and integrates with native DICOM tools and workflows.

Which medical specialties are these tools designed for?

Bunkerhill ECG-EF is relevant for Cardiology, Emergency Medicine, and Internal Medicine. Imbio PHA (4.0.0) targets Cardiology, Pulmonology, and Radiology specialties.

What is the output format or reporting method for each tool?

Bunkerhill ECG-EF is a software-only medical device that provides AI algorithm output to aid in identification and supports automated clinical workflows. Imbio PHA (4.0.0) generates annotated DICOM images and provides summary reports in PDF format.

What is the primary benefit of using each tool in patient care?

Bunkerhill ECG-EF offers a non-invasive, rapid, and accessible cardiac diagnostic tool for early identification of patients at risk for heart failure using routine ECGs. Imbio PHA (4.0.0) provides rapid, fully-automated assessment of cardiac structures from CTPA scans to aid in the diagnosis and risk stratification of pulmonary embolism and hypertension.